Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros


Bases de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
2.
Acta Leprol ; 9(3): 133-7, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-7631584

RESUMO

This study reports the clinical profile and therapeutic response of seventy-two mono-lesions leprosy cases. These 72 cases were among 578 paucibacillary (PB) cases classified according to WHO (1982) and were followed-up on multidrug therapy (MDT). Of these 72 mono-lesion cases, 46 (64%) were tuberculoid (TT) cases, 24 (33%) were Indeterminate (Ind) cases and 2 (3%) were of borderline tuberculoid (BT) types. While 37.5% of these cases presented as macular patches, the remaining 62.5% had raised erythematous lesions. In majority of cases (94%), the lesions were present on the exposed parts like legs and feet, arms and hands, face, whereas only 6% presented on covered areas of trunk and buttocks. These cases were treated with dapsone 100 mg daily for 12 months and rifampicin 600 mg once a month for 6 months. After 6 months of MDT, lesions in 81% of the patients regressed clinically and by one year of therapy 96% of cases had regressed. Treatment was stopped in all cases by one year of therapy. There were no relapse or late reaction in the 5 years of post treatment follow-up. The response of mono-lesion PB cases was better than the multi-lesions PB cases at 6 months and during the post treatment follow-up period.


Assuntos
Dapsona/uso terapêutico , Hanseníase Tuberculoide/tratamento farmacológico , Rifampina/uso terapêutico , Adolescente , Adulto , Braço , Dapsona/administração & dosagem , Quimioterapia Combinada , Dermatoses Faciais/tratamento farmacológico , Dermatoses Faciais/microbiologia , Dermatoses Faciais/patologia , Seguimentos , Humanos , Dermatoses da Perna/tratamento farmacológico , Dermatoses da Perna/microbiologia , Dermatoses da Perna/patologia , Hanseníase Dimorfa/tratamento farmacológico , Hanseníase Dimorfa/patologia , Hanseníase Tuberculoide/patologia , Pessoa de Meia-Idade , Recidiva , Indução de Remissão , Rifampina/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA